RABEPRAZOLE

SynDRA canonical compound SYN0004668 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	ATP4A
Mechanism of action	Gastrin inhibitor
Indication	duodenal ulcer disease \| gastroesophageal reflux disease (GERD) \| Zollinger-Ellison syndrome
Disease area	gastroenterology

All known targets

sodium rabeprazole
rabeprazole sodium
habeprazole
aciphex
rabeprazole sodium salt
Rabeprazol
Eraloc
Ly-307640
Pariprazole
E-3810 (PPI)
E3810
LY307640
Dexrabeprazole
Rebeprazole sodium
CL23619
Aciphex (TN)
Eraloc (TN)
Pariet (TN)
Rabeprazole (INN)
Rabeprazole [BAN:INN]
Rabeprazole [INN:BAN]
Rablet (TN)
2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole
2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole
2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole
Aciphex
Habeprazole
pariprazole
Pariets
2-(((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
CHEBI:8768
LY 307640
RABEPRAZOLE [INN]
32828355LL
1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-
1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-
2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methane}sulfinyl)-1H-1,3-benzodiazole